Exploring the effect of the axial ligands on the anticancer activity of [C,N,N′] Pt(<scp>iv</scp>) cyclometallated compounds-Reference-Cited by-同舟云学术

Exploring the effect of the axial ligands on the anticancer activity of [C,N,N′] Pt(iv) cyclometallated compounds

Published:2024 Issue:31 Volume:53 Page:13030-13043
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Lázaro Ariadna¹²^ORCID,Bosque Ramón¹^ORCID,Marín Silvia³⁴⁵^ORCID,Pérez-León Raúl⁴,Badia Josefa³⁶^ORCID,Baldomà Laura³⁶^ORCID,Rodríguez Laura¹²^ORCID,Crespo Margarita¹³^ORCID,Cascante Marta³⁴⁵^ORCID

Affiliation:

1. Departament de Química Inorgànica i Orgànica, Secció de Química Inorgànica, Facultat de Química, Universitat de Barcelona, E-08028-Barcelona, Spain

2. Institut de Nanociència i Nanotecnologia (IN2UB), Universitat de Barcelona, E-08028 Barcelona, Spain

3. Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, E-08028 Barcelona, Spain

4. Departament de Bioquímica i Biomedicina molecular, Facultat de Biologia, Universitat de Barcelona, E-08028-Barcelona, Spain

5. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

6. Departament de Bioquímica i Fisiologia, Secció de Bioquímica i Biologia Molecular, Facultat de Farmàcia, E-08028-Barcelona, Spain

Abstract

The anticancer activity of [C,N,N′] Pt(iv) cyclometallated compounds with different axial ligands is higher for the most easily reduced compounds while the efficiency of binding to DNA is less relevant.

Funder

Ministerio de Ciencia e Innovación

Agència de Gestió d'Ajuts Universitaris i de Recerca

Instituto de Salud Carlos III

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/DT/D4DT01225A

Reference84 articles.

1. Dr Barnett Rosenberg – a Personal Perspective

2. Multi-action Pt(IV) anticancer agents; do we understand how they work?

3. Platinum(iv) anticancer prodrugs – hypotheses and facts

4. Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?

5. Basis for Design and Development of Platinum(IV) Anticancer Complexes